Venous thromboembolic diseases: diagnosis, management and thrombophilia testing

sources of hypercoagulability • increase the dose of anticoagulant or change to an anticoagulant with a different mode of action. [2020] NICE technology appraisal guidance on anticoagulation treatment for confirmed DVT or PE For direct-acting oral anticoagulants recommended as options in NICE technology appraisal guidance for treating and preventing confirmed DVT or PE, see the guidance on: • edoxaban (TA354, August 2015) • apixaban (TA341, June 2015) • dabigatran etexilate (TA327, December 2014) • rivaroxaban (TA287, June 2013 and TA261, July 2012). For a short explanation of why the committee made the 2020 recommendations and how they might affect practice, see the rationale and impact section on anticoagulation treatment for confirmed DVT or PE. Full details of the evidence and the committee's discussion are in evidence review D: pharmacological treatment in people with suspected or confirmed deep vein thrombosis and/or pulmonary embolism. Evidence review G: economic modelling report for pharmacological treatment also underpins recommendations 1.3.8, 1.3.9, 1.3.17 and 1.3.18. 1.4 Long-term anticoagulation for secondary prevention 1.4.1 Assess and discuss the benefits and risks of continuing, stopping or changing the anticoagulant with people who have had anticoagulation treatment for 3 months (3 to 6 months for people with active cancer) after
